6-substituted-thio-2-amino-quinoline derivatives useful as...

Details 6-substituted-thio-2-amino-quinoline derivatives useful as... 6-substituted-thio-2-amino-quinoline derivatives useful as...

2009-01-27

2011-12-13

Lundgren, Jeffrey S (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S159000

Reexamination Certificate

active

08076358

ABSTRACT:
The present invention is directed to 6-substituted-thio-2-amino-quinoline derivatives, pharmaceutical compositions containing them and their use in the treatment of Alzheimer's disease (AD), mild cognitive impairment, senility and/or dementia. The compounds of the present invention are inhibitors of β-secretase, also known as β-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2.

REFERENCES:
patent: 3138595 (1964-06-01), Osdene et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4675047 (1987-06-01), Serban et al.
patent: 4739056 (1988-04-01), Venuti et al.
patent: 4761416 (1988-08-01), Fried et al.
patent: 5387742 (1995-02-01), Cordell
patent: 5580003 (1996-12-01), Malone et al.
patent: 5612486 (1997-03-01), McConlogue et al.
patent: 5672805 (1997-09-01), Neve
patent: 5720936 (1998-02-01), Wadsworth et al.
patent: 5811633 (1998-09-01), Wadsworth et al.
patent: 5877015 (1999-03-01), Hardy et al.
patent: 5877399 (1999-03-01), Hsiao et al.
patent: 6037521 (2000-03-01), Sato et al.
patent: 6071903 (2000-06-01), Albright et al.
patent: 6184435 (2001-02-01), Benson et al.
patent: 6187922 (2001-02-01), Geen et al.
patent: 6211428 (2001-04-01), Singh et al.
patent: 6340783 (2002-01-01), Snow
patent: 7531545 (2009-05-01), Baxter et al.
patent: 7776882 (2010-08-01), Baxter et al.
patent: 7786116 (2010-08-01), Baxter et al.
patent: 7868022 (2011-01-01), Baxter et al.
patent: 7932261 (2011-04-01), Baxter et al.
patent: 2004/0087548 (2004-05-01), Salvati et al.
patent: 2004/0209905 (2004-10-01), Kubo et al.
patent: 2005/0171111 (2005-08-01), Angibaud et al.
patent: 2006/0074105 (2006-04-01), Ware, Jr. et al.
patent: 2006/0079686 (2006-04-01), Baxter et al.
patent: 2006/0079687 (2006-04-01), Baxter et al.
patent: 2006/0178383 (2006-08-01), Bischoff et al.
patent: 406958 (1991-01-01), None
patent: 371564 (1995-07-01), None
patent: 1407774 (2004-04-01), None
patent: 63-196573 (1988-08-01), None
patent: 04 011255 (1992-01-01), None
patent: 01/38314 (2001-05-01), None
patent: 01/38315 (2001-05-01), None
patent: 02/100399 (2002-12-01), None
patent: 2004/022523 (2004-03-01), None
patent: 2004/058686 (2004-07-01), None
patent: 2004/063172 (2004-07-01), None
patent: 2005/049585 (2005-06-01), None
patent: 2006/017836 (2006-02-01), None
patent: 2006/017844 (2006-02-01), None
patent: 2006/024932 (2006-03-01), None
patent: 2006/078577 (2006-07-01), None
patent: 2007/050612 (2007-05-01), None
patent: 2007/092846 (2007-08-01), None
patent: 2007/092854 (2007-08-01), None
patent: WO 2007/092854 (2007-08-01), None
International Search Report re: PCT/US2009/032126 dated Mar. 30, 2009.
Office Action mailed May 29, 2008 in U.S. Appl. No. 11/197,669.
Office Action mailed Aug. 21, 2008 in U.S. Appl. No. 11/197,669.
Office Action mailed Apr. 29, 2009 in U.S. Appl. No. 11/197,669.
Notice of Allowance mailed Dec. 8, 2009 in U.S. Appl. No. 11/197,669.
Notice of Allowance mailed Nov. 15, 2010 in U.S. Appl. No. 11/197,669.
Office Action mailed May 30, 2008 in U.S. Appl. No. 11/197,608.
Office Action mailed Aug. 20, 2008 in U.S. Appl. No. 11/197,608.
Office Action mailed Apr. 30, 2009 in U.S. Appl. No. 11/197,608.
Notice of Allowance dated Dec. 8, 2009 in U.S. Appl. No. 11/197,608.
Office Action mailed Apr. 28, 2011 in U.S. Appl. No. 11/197,608.
Office Action mailed May 29, 2008 in U.S. Appl. No. 11/197,615.
Office Action mailed Jan. 27, 2009 in U.S. Appl. No. 11/197,615.
Office Action mailed Sep. 29, 2009 in U.S. Appl. No. 11/197,615.
Notice of Allowance mailed Apr. 19, 2010 in U.S. Appl. No. 11/197,615.
Office Action mailed Jun. 19, 2009 in U.S. Appl. No. 11/671,681.
Office Action mailed Sep. 29, 2009 in U.S. Appl. No. 11/671,681.
Notice of Allowance mailed May 4, 2010 in U.S. Appl. No. 11/671,681.
Notice of Allowance mailed Aug. 23, 2010 in U.S. Appl. No. 11/671,681.
Office Action mailed Jun. 19, 2008 in U.S. Appl. No. 11/671,703.
Office Action mailed Aug. 20, 2008 in U.S. Appl. No. 11/671,703.
Office Action mailed Feb. 12, 2009 in U.S. Appl. No. 11/671,703.
Office Action mailed Jun. 9, 2009 in U.S. Appl. No. 11/671,703.
Notice of Allowance mailed Nov. 19, 2009 in U.S. Appl. No. 11/671,703.
Notice of Allowance mailed Mar. 17, 2010 in U.S. Appl. No. 11/671,703.
Office Action mailed Mar. 24, 2009 in U.S. Appl. No. 11/671,732.
Notice of Allowance mailed Sep. 25, 2009 in U.S. Appl. No. 11/671,732.
Notice of Allowance mailed Jan. 6, 2010 in U.S. Appl. No. 11/671,732.
Notice of Allowance mailed Apr. 16, 2010 in U.S. Appl. No. 11/671,732.
Notice of Allowance mailed Jul. 26, 2010 in U.S. Appl. No. 11/671,732.
Notice of Allowance mailed Dec. 15, 2010 in U.S. Appl. No. 11/671,732.
Notice of Allowance mailed Apr. 14, 2010 in U.S. Appl. No. 12/362,020.
Notice of Allowance mailed Dec. 24, 2009 in U.S. Appl. No. 12/362,020.
Office Action mailed Sep. 10, 2009 in U.S. Appl. No. 12/362,020.
Citron, Trends in Pharm. Sci., vol. 25, Issue 2, Feb. 2004, 92-97.
Cole, et al., Molecular Neurodegeneration 2007, 2:22.
Database Caplus “Online!” Chemical Abstracts Service, Columbus, Ohio, US. Ishikawa, Fumyoshi et al.: “Quinazolineacetic acid derivatives as platelet aggregation inhibitors”. XP00236713. (1988).
Ermolieff et al., Biochemistry, (2000) vol. 39, p. 12450.
El Mouedden, M. et al., (Johnson & Johnson Pharmaceutical Research and Development, Division of Janssen Pharmaceutica N. V., Turnhoutseweg 30, Beerse, Belg.), Development of a specific ELISA for the quantitative study of amino-terminally truncated beta-amyloid peptides,. Journal of Neuroscience Methods (2005), 145(1-2), pp. 97-105.
Games, D. et al., (Athena Neurosciences, Inc., South San Francisco, CA, USA), Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein, Nature (London) (1995), 373(6514), pp. 523-527 (V717F mice).
Hamaguchi, et al., Cell. Mol. Life Sci. 63 (2006) 1538-1552.
Hsiao, K. et al., (Dep. Neurology, Univ. Minnesota, Minneapolis, MN, USA), Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice, Science (Washington, D. C.) (1996), 274(5284), pp. 99-102 (Tg2576 mice).
Kienzle, F. et. al., Chemical Abstract, 1983, vol. 98, Abstract No. 143363, (or CAPLUS Accession No. 1983:143363).
Kienzle, F., et al. “1,5-Dihydroimdazoquinazoliones as Blood Platelet Aggregation Inhibitors”, European Journal of Medicinal Chemistry, 17(6), 547-556, 1982.
Larner, A.J.: “Secretases as Therapeutic Targets in Alzheimer's Disease: Patents 2000 2004”. Expert Opinion On Therapeutic Patents, Ashley Publications, GB, vol. 14, No. 10, 2004, pp. 1403-1420, XP002404250.
Lewczuk, P. et al., (Department of Psychiatry and Psychotherapy, Molecular Neurobiology Lab, University of Erlangen-Nuremberg, Erlangen, Germany), Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau, Neurobiology of Aging (2004), 25(3), pp. 273-281.
Lins, H. et al., (Department of Neurology, Otto-von-Guericke-University, Magdeburg, Germany), Immunoreactivities of amyloid β peptide(1-42) and total τ protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus, Journal of Neural Transmission (2004), 111(3), pp. 273-280.
Neve, R. L. et al., (Dep. Genetics, Harvard Medical School and McLean Hospital, Belmont, MA, USA), Transgenic mice expressing APP-C100 in the brain, Neurobiology of Aging (1996), 17(2), pp. 191-203 (APP-C100 mice).
Oddo, S. et al, (Department of Neurobiology and Behavior, University of California, Irvine, Irvine, CA, USA), Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Aβ and synaptic dysfunction, Neuron (2003), 39(3), pp. 409-421 (APP Triple Transgenic Mice).
Olsson, A. et al., (Sahlgrenska University Hospital, Experimental Neuroscience Section, Institute of Clinical Neuroscience, Goteborg University, Moelndal, Sweden), Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients, Experimental Neurology (2003), 183(1), pp. 74-80.
Ruberti et al

Affiliated with

Also associated with

Rating

6-substituted-thio-2-amino-quinoline derivatives useful as... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 6-substituted-thio-2-amino-quinoline derivatives useful as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 6-substituted-thio-2-amino-quinoline derivatives useful as... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4295915